Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Decreases By 7.3%

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 4,330,000 shares, a decrease of 7.3% from the January 15th total of 4,670,000 shares. Based on an average daily volume of 826,100 shares, the short-interest ratio is currently 5.2 days.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on FULC shares. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Stock Up 2.0 %

NASDAQ:FULC traded up $0.08 during trading hours on Tuesday, reaching $3.77. 269,938 shares of the company’s stock were exchanged, compared to its average volume of 476,454. The company has a market capitalization of $203.08 million, a P/E ratio of -12.14 and a beta of 2.03. Fulcrum Therapeutics has a 12 month low of $2.86 and a 12 month high of $13.70. The business’s 50-day simple moving average is $4.20 and its two-hundred day simple moving average is $4.84.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of FULC. Charles Schwab Investment Management Inc. increased its stake in Fulcrum Therapeutics by 223.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock worth $2,032,000 after purchasing an additional 393,202 shares in the last quarter. State Street Corp increased its position in shares of Fulcrum Therapeutics by 61.4% in the third quarter. State Street Corp now owns 1,680,229 shares of the company’s stock worth $5,998,000 after acquiring an additional 638,955 shares in the last quarter. Barclays PLC raised its holdings in shares of Fulcrum Therapeutics by 367.1% during the third quarter. Barclays PLC now owns 124,141 shares of the company’s stock valued at $443,000 after acquiring an additional 97,565 shares during the period. Braidwell LP purchased a new stake in shares of Fulcrum Therapeutics in the 3rd quarter valued at approximately $3,817,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Fulcrum Therapeutics in the 3rd quarter worth approximately $474,000. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.